Evidence map›Paper›PMID 15657119›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2005

Metabolizing enzyme toxicology assay chip (MetaChip) for high-throughput microscale toxicity analyses.

Moo-Yeal Lee, Chan Beum Park, Jonathan S Dordick, Douglas S Clark

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
14.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 161 citations in OpenAlex.

  1. Review
  2. Article
  3. Advances in Engineered Human Liver Platforms for Drug Metabolism Studies.Drug metabolism and disposition: the biological fate of chemicals · 2018
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Life on a microarray: assessing live cell functions in a microarray format.Cellular and molecular life sciences : CMLS · 2012
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Moo-Yeal LeeDepartment of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, NY 12180, USA.
Chan Beum Park
Jonathan S Dordick
Douglas S Clark
Rensselaer Polytechnic Institute · USUniversity of California, Berkeley · US

Funding

Integrated Biochip for In-Vitro ToxicologyR42ES012619 · NIEHS · SOLIDUS BIOSCIENCES, INC. · PI DORDICK, JONATHAN S. · 2005 to 2007
$1.7M
Integrated Biochip for In-Vitro ToxicologyR41ES012619 · NIEHS · SOLIDUS BIOSCIENCES, INC. · PI DORDICK, JONATHAN S. · 2003 to 2004
$499k
NIEHS NIH HHS ES-012619NIEHS NIH HHS R41 ES012619NIEHS NIH HHS R42 ES012619
6 · The paper itself

Abstract

The clinical progression of new chemical entities to pharmaceuticals remains hindered by the relatively slow pace of technology development in toxicology and clinical safety evaluation, particularly in vitro approaches, that can be used in the preclinical and early clinical phases of drug development. To alleviate this bottle-neck, we have developed a metabolizing enzyme toxicology assay chip (MetaChip) that combines high-throughput P450 catalysis with cell-based screening on a microscale platform. The MetaChip concept is demonstrated by using sol-gel encapsulated P450s to activate the prodrug cyclophosphamide, which is the major constituent of the anticancer drug Cytoxan, as well as other compounds that are activated by P450 metabolism. The MetaChip provides a high-throughput microscale alternative to currently used in vitro methods for human metabolism and toxicology screening based on liver slices, cultured human hepatocytes, purified microsomal preparations, or isolated and purified P450s. This technology creates opportunities for rapid and inexpensive assessment of ADME/Tox (absorption, distribution, metabolism, excretion/toxicology) at very early phases of drug development, thereby enabling unsuitable candidates to be eliminated from consideration much earlier in the drug discovery process.

Indexed as

BiotransformationCatalysisCyclophosphamideCytochrome P-450 Enzyme SystemHumansPhase TransitionToxicity TestsCyclophosphamideCytochrome P-450 Enzyme System

Identifiers

PMID15657119
PMCPMC545843
OpenAlexW2065137641

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.